Local anaesthetic bupivacaine induced ovarian and prostate cancer apoptotic cell death and underlying mechanisms in vitro by Xuan, W et al.
1Scientific RepoRts | 6:26277 | DOI: 10.1038/srep26277
www.nature.com/scientificreports
Local anesthetic bupivacaine 
induced ovarian and prostate 
cancer apoptotic cell death and 
underlying mechanisms in vitro
Wei Xuan1,2,3, Hailin Zhao3, James Hankin3, Lin Chen2,3, Shanglong Yao2 & Daqing Ma3
Retrospective studies indicate that the use of regional anesthesia can reduce cancer recurrence 
after surgery which could be due to ranging from immune function preservation to direct molecular 
mechanisms. This study was to investigate the effects of bupivacaine on ovarian and prostate cancer 
cell biology and the underlying molecular mechanisms. Cell viability, proliferation and migration of 
ovarian carcinoma (SKOV-3) and prostate carcinoma (PC-3) were examined following treatment with 
bupivacaine. Cleaved caspase 3, 8 and 9, and GSK-3β, pGSK-3βtyr216 and pGSK-3βser9 expression were 
assessed by immunofluorescence. FAS ligand neutralization, caspase and GSK-3 inhibitors and GSK-3β 
siRNA were applied to further explore underlying mechanisms. Clinically relevant concentrations of 
bupivacaine reduced cell viability and inhibited cellular proliferation and migration in both cell lines. 
Caspase 8 and 9 inhibition generated partial cell death reversal in SKOV-3, whilst only caspase 9 was 
effective in PC-3. Bupivacaine increased the phosphorylation of GSK-3βTyr216 in SKOV-3 but without 
measurable effect in PC3. GSK-3β inhibition and siRNA gene knockdown decreased bupivacaine 
induced cell death in SKOV-3 but not in PC3. Our data suggests that bupivacaine has direct ‘anti-cancer’ 
properties through the activation of intrinsic and extrinsic apoptotic pathways in ovarian cancer but 
only the intrinsic pathway in prostate cancer.
Cancer recurrence and metastasis are significant causes of death in cancer patients1. Surgical resection of solid 
tumors can be curative. However, surgery itself inducing stress responses is immunosuppressive and the inadvert-
ent seeding of cancer cells may also occur during an operation. This increases the risk of tumor metastasis during 
the perioperative period2,3.
During surgery, local/regional anesthesia (LA/RA) techniques are used for various reasons in cancer patients. 
These can range from pain management to decrease opioid use4–6. In light of the potential benefits of LA/RA use 
in cancer patients, there has been an increased focus on investigating the mechanisms involved7. Retrospective 
studies indicate that the use of LA/RA decreases the risk of metastasis, cancer recurrence, and improves overall 
survival8,9. More specifically and relevant to this study, decreased cancer recurrence has been reported with the 
use of epidural anesthesia in ovarian and prostate carcinomas10,11.
There is a strong association between the use of LA/RA and the preservation of cell mediated immunity sur-
gical stress response modulation12. Recent in vitro studies have examined the underlying molecular mechanisms 
of local anesthetics and cancer cell biology13,14. Despite this progress, knowledge of potential direct mechanisms 
is limited.
The aim of this study is to investigate the effects of the commonly used local anesthetic bupivacaine on 
the viability, proliferation and migration properties of human ovarian carcinoma and prostate carcinoma cell 
lines. Furthermore, bupivacaine induced cancer cell death and potential underlying molecular mechanisms are 
explored. A novel approach is utilized, with a focus on the activity of glycogen synthase kinase-3β (GSK-3β ), a 
multifunctional enzyme involved in numerous cellular processes. We investigated its potential interactions with 
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bupivacaine on cancer cell biology. In this context, the phosphorylation activity of GSK-3β ’s residues of tyrosine 
(active form) or serine (inactive form)15 was investigated.
Results
Bupivacaine on cancer cell viability and chemotherapy sensitivity. Bupivacaine at 1 mM decreased 
cell viability in both cell lines. Statistically significant effects were not observed at lower concentrations. A greater 
degree of cytotoxicity was exhibited when the treatment duration was 72 hours (Fig. 1A–D). Potentially different 
cytotoxic profiles between healthy and cancer cells to bupivacaine treatment were also explored. For this purpose, 
healthy human renal tubular epithelial (HK-2) cells were utilized. Interestingly, the change of cell viability in 
HK-2 was found to be not as significant as cancer cells after being treated with bupivacaine for 24 hours (Fig. 1E). 
This indicates that cancer cells, which are metabolically more active than their healthy equivalents, are more sus-
ceptible to bupivacaine’s cytotoxic properties. The synergetic effect of bupivacaine with chemotherapy agent taxol 
was also noted in both cell lines. Bupivacaine potentiated the toxic effects of taxol following 24 hours treatment. 
At doses of 100 μ M or 1 mM, bupivacaine augmented the cytotoxicity of taxol at a dose of 100 nM (Fig. 1F,G).
Bupivacaine on cancer cell apoptosis. Caspase 3, 8 and 9 were activated in SKOV-3 following 1 mM 
bupivacaine treatment at 24 hours (Fig. 2A–C), with caspases 3 and 9 being cleaved in PC-3 (Fig. 2D–F). Cleaved 
caspase 3 expression through western blot were both elevated in two cancer cell lines after the treatment of 1mM 
bupivacaine (Fig. 2G). Caspase 9 inhibitor partially reversed bupivacaine induced SKOV-3 and PC-3 cell death 
(Fig. 3B), whilst Caspase 8 inhibition was effective in SKOV-3 only (Fig. 3A). Cytotoxicity was independent from 
FAS receptor activity as FAS ligand neutralization antibody treatment did not yield significant results as detected 
by flow cytometry (Fig. 3C,D).
Bupivacaine on cancer cell proliferation and ROS production. Bupivacaine treatment (1 mM ) for 
24 hours induced a statistically significant reduction in Ki-67 positive cells when compared to control groups in 
SKOV-3 (57.3% versus 30.1%, p < 0.01) and PC-3 cells (68.4% versus 36.7%, p < 0.001) (Fig. 4A,B). Bupivacaine 
induced a statistically significant increase in ROS generation in SKOV-3 (Fig. 4C), whereas ROS level decreased 
in PC-3 cells (Fig. 4D).
Bupivacaine on cancer cell migration. Wound healing assay was utilized to investigate the effects of 
bupivacaine on the migration potential of both cell lines. Following 24 hour bupivacaine treatment, fewer cells 
migrated towards the scratch midline in 1 mM bupivacaine treated group when compared to the control groups 
(Fig. 5A,B). Bupivacaine reduced migration potential of PC-3 cells by up to 60% (Fig. 5B). Lower concentrations 
of bupivacaine did not impact on cancer cell migration (data not shown).
Figure 1. Bupivacaine alone and combined with anti-cancer drug decreased viability of both ovarian 
cancer (SKOV-3) and prostate cancer (PC-3) cells. SKOV-3 and PC-3 cells were treated with bupivacaine 
(Bupi) from 1 μ M to 1 mM for 24 or 72 h and cell survival was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. (A) SKOV-3 cells with bupivacaine for 24 h. (B) SKOV-3 cells with 
bupivacaine for 72 h. (C) PC-3 cells with bupivacaine for 24 h. (D) PC-3 cells with bupivacaine for 72 h. (E) The 
viability of HK-2 cells treated with bupivacaine at 1 mM for 24 h. The viability of SKOV-3 (F) and PC-3 (G) were 
treated with bupivacaine (100 μ M and 1 mM) plus anti-cancer drug taxol (100 nM) for 24 h. Data are presented 
as mean ± SD (n = 5). *P < 0.05; **P < 0.01; ***P < 0.001.
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Bupivacaine on GSK-3β expression. Varying levels of increased expression in total GSK-3β , pGSK-3β tyr216 
and pGSK-3β ser9 were demonstrated using immunofluorescence. In SKOV-3 cells, baseline levels of total GSK-3β 
and pGSK-3β tyr216 were similar and almost doubled following bupivacaine treatment when compared with con-
trol (Fig. 6A,B). The baseline level and elevation of pGSK-3β ser9 was relatively lower (Fig. 6C). With reference to 
the PC-3 cell line following bupivacaine treatment, similar basal expression levels of GSK-3β , pGSK-3β tyr216 and 
pGSK-3β ser9 were observed and these were not statistically significant (Fig. 6D–F).
GSK-3 inhibition on bupivacaine induced SKOV-3 cell death. GSK-3 pharmacological inhibitor 
SB-216763 and GSK-3β siRNA (gene knockdown) were used to examine potential GSK-3β activity in bupiv-
acaine induced cell death. Total GSK-3β expression was almost abolished following GSK-3β siRNA treatment 
through western blot (Fig. 7C). Inhibition and gene knockdown both reduced the cytotoxic effects of bupivacaine 
induced SKOV-3 cell death (Fig. 7A,D). These reagents themselves did not have an effect in PC-3 cells (Fig. 7B,E). 
Following GSK gene knockdown, decreased caspase 3, 8, 9 cleavage and pGSK-3β tyr216 activity was observed 
(Fig. 8A–C).
Discussion
This study indicates that bupivacaine possesses cytotoxic, anti-proliferative and anti-metastatic properties in both 
ovarian and prostate cancer cell lines. Following 24 hours treatment, 1mM bupivacaine induced similar levels of 
cytotoxicity in both cell lines. Cell death was more pronounced after treatment for 72 hours. This is contrasted 
by the lack of statistical significant cell death exhibited by HK-2 cells when treated with 1mM bupivacaine. This 
may indicate different cell lines (cancerous vs non-cancerous) have varying levels of sensitivity to bupivacaine. 
Furthermore, an synergistic effect was observed when bupivacaine was combined with the chemotherapy agent 
taxol. Data is limited on potential mechanisms, but as shown in (Fig. 9) the activation of the intrinsic and extrin-
sic apoptotic pathways in conjunction with the active form of GSK-3β are likely to be involved (Fig. 9).
Figure 2. Bupivacaine changed cleaved-caspase expression in both ovarian cancer (SKOV-3) and prostate 
cancer (PC-3) cells. Cells were treated with 1 mM bupivacaine (Bupi) for 24 h followed by immunostaining and 
western blot. (A) Caspase 3, (B) Caspase 8, (C) Caspase 9 expression in SKOV-3 cells. (D) Caspase 3, (E) Caspase 8, 
(F) Caspase 9 expression in PC-3 cells. (G) Cleaved caspase 3 expression in SKOV-3 and PC-3 by western blot. Data 
are presented as mean ± SD. (n = 4). ***P < 0.001. Scale bar = 50 μ m.
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Data indicates there is an association between changes in cellular metabolism and the rate of cellular pro-
liferation in cancer cells16. Beitner et al. reported that LA reduced melanoma cells glycolysis and ATP levels 
by downregulating two allosteric stimulatory signal molecules17. Lucchinetti et al. suggested that LA inhibited 
mesenchymal stem cells (MSC) proliferation18. Ki-67, a key marker of proliferation19, was used in our study to 
examine the effects of LA on cellular proliferation. Our results show decreased Ki67 expression in both SKOV-3 
and PC-3 cell lines treated with 1 mM bupivacaine.
Lucchinetti et al.18 reported that 100 μ M ropivacaine significantly inhibited mesenchymal stem cell migration 
as measured by wound healing assay. Our study demonstrates that 1 mM bupivacaine inhibits the migration 
potential of SKOV-3 and PC-3. Greater inhibition was observed in PC-3. Data indicates that prostate cancer 
exhibits higher levels of metastatic potential20. This may suggest that the anti-migration properties of LA may 
have a greater impact on more invasive tumors.
Reactive oxygen species (ROS) activity was also determined in the current study. It has been reported that 
increased ROS levels suppresses breast cancer cell proliferation21, whilst opposite finding also exists is that anti-
oxidants can inhibit liver cancer cell proliferation22. Our study demonstrates increased ROS levels in SKOV-3, 
whilst decreased ROS levels in PC-3. These results are in keeping with the contradictory role ROS activity appears 
to have in cancer cell growth/proliferation21,22 and requires further investigation.
Previous studies indicate that LA induced cancer cell death is caspase dependent23. Werdehausen et al.24 used 
gene modulation techniques and demonstrated that low concentrations of lidocaine induced Jurkat cell death 
via the intrinsic apoptotic pathway. We found that caspase 3, 8 and 9 were activated in SKOV-3 following 1 mM 
bupivacaine treatment while caspase 3 and 9 were cleaved in PC-3. Furthermore, partial cell death inhibition 
was observed with caspase 9 inhibition in both cell lines. Caspase 8 inhibition was only effective in SKOV-3. It 
has been noticed that mutations in tumor suppressor genes; such as BRCA1 in ovarian cancer, have a significant 
function in DNA damaging related apoptosis in cancer chemotherapy25. Local anesthetics have also demonstrated 
to be potent DNA damaging agents. Kim et al. demonstrated that dibucaine induced DNA fragmentation and 
chromatin condensation in neuroblastoma cells26. It is to be determined if genomic defects increase the cytotoxic 
profile of bupivacaine in ovarian and prostate cancer.
The caspase cascade involves numerous cellular processes; of which FAS ligand activity is implicated. This 
study indicates FAS ligand receptor activity is not involved in bupivacaine interactions with SKOV-3 or PC-3. 
It has been reported that caspase 8 activation not only occurs via FAS/death receptor ligand27, but also via FAS 
Figure 3. Effects of caspase 8 and 9 inhibition or Fas ligand neutralizing antibody on bupivacaine induced 
of ovarian cancer (SKOV-3) and prostate cancer (PC-3) cell death. Cells were pre-treated with 20 μ M either 
caspase 8 inhibitor (Z-IETD-FMK) or caspase 9 inhibitor (Z-LEHD-FMK) 4 h before being superposed with 
1 mM bupivacaine for 24 h. (A) Cell survival of caspase 8 inhibition in SKOV-3 and PC-3 cells. (B) Cell survival 
caspase 9 inhibition in SKOV-3 and PC-3 cells. Percentage of dead cells by the treatment of 500 ng/ml anti-
Fas antibody (human, neutralizing, clone ZB4) in (C) SKOV-3 cells and (D) PC-3 cells. Data are presented as 
mean ± SD (n = 5). *P < 0.05; **P < 0.01; ***p < 0.001.
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Figure 4. Bupivacaine treatment reduced cell proliferation and modulated oxidative stress of both ovarian 
cancer (SKOV-3) and prostate cancer (PC-3) cells. Cells were treated with 1 mM bupivacaine (Bupi) for 24 h 
for proliferation study, and 4 h treatment for reactive oxygen species (ROS) detection. (A) Ki-67 expression 
in (A) SKOV-3 cells and (B) PC-3 cells. (C) ROS generation in (C) SKOV-3 cells and (D) PC-3 cells. Data are 
presented as mean ± SD (n = 4). *P < 0.05; **P < 0.01; ***P < 0.001.
www.nature.com/scientificreports/
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ligand independent caspase 8 induced cell death28. This suggests different cancer cells exhibit varying biological 
profiles which influence molecular signal transduction processes involved in growth, development and death.
Glycogen synthase kinase-3β (GSK-3β ) is a serine/threonine kinase which is implicated in numerous cell 
functions including cell differentiation, proliferation and apoptosis. GSK-3β leads cell apoptosis via the interac-
tion with proapoptotic transcription factor p53 as its regulatory protein, and it also cause apoptosis by inducing 
mitochondrial injury and the caspase cascade29,30. Phosphorylation at its tyrosine residue (tyr-216) constitutes 
its active form whereas serine residue (ser-9) phosphorylation is its inactive form31. The role of GSK3β in tumor 
development is controversial. Previous studies have shown that GSK3β impaired tumor growth in several cancer 
cell lines32,33. However, Cao et al.34 reported that the suppression of kinase inactive form GSK3β ser9 promoted 
ovarian cancer development, which indicated GSK3β is also necessary for tumor survival. Furthermore, another 
study showed that the suppression of Src-GSK3β axis could be a new target to treat prostate cancer35. GSK3β 
interactions with chemotherapy agents are complicated. There is increasing evidence which indicates that GSK3β 
activity modulates the effectiveness of chemotherapy on cancer cells. Downregulation of GSK3β expression level 
conferred resistance of ovarian cancer cells from cisplatin treatment36. In hepatoblastoma cell lines, GSK3β inhi-
bition by pharmacological or gene knockdown/mutant techniques limited anti-cancer drug induced apoptosis37. 
Consistent with these findings, our study demonstrates GSK3β expression is essential for bupivacaine induced 
cell death. Total GSK3β , pGSK-3β ser9 and pGSK-3β tyr216 were all elevated in SKOV-3 cells following 24 hours 
of treatment with 1 mM bupivacaine. Greater levels of expression were observed in pGSK-3β tyr216, the active 
form of GSK3β , when compared with the inactive form pGSK-3β ser9. Previous reports have primarily focused 
on GSK-3β ser9 or GSK-3β tyr216 expression in isolation. Our findings indicate that whilst both were activated, an 
overall increase in the expression of GSK-3β is observed. Statistically significant changes in expression of GSK3β, 
pGSK-3β ser9 and pGSK-3β tyr216 were not observed in the PC-3 cell line. This indicates that bupivacaine induced 
prostate cancer cell death is unlikely to involve GSK3β activity.
To further examine GSK-3β activity and the relative expression of its residues, GSK3β inhibition demonstrated 
the partial suppression of cell death in bupivacaine treated SKOV-3 cells. This suggests GSK3β is pro-apoptotic in 
Figure 5. Bupivacaine treatment inhibited cell migration of both ovarian cancer (SKOV-3) and prostate 
cancer (PC-3) cells. Scratched monolayer cells were treated with 1 mM bupivacaine for 24 h. Degree of wound 
healing was calculated as (initial wound area − remaining wound area)/initial wound area. (A) Bupivacaine 
suppressed wound closure in SKOV-3 cells. (B) Bupivacaine suppressed wound closure in PC-3 cells. All values 
are presented as mean ± SD (n = 4); ***P < 0.001.
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bupivacaine induced cell death. To investigate potential interactions between GSK3β and caspase activity in apop-
tosis, we demonstrated that caspase 3, 8 and 9 were down regulated following GSK3β siRNA treatment, which 
reaffirmed the hypothesis that GSK3β deactivation in the SKOV-3 confers resistance to bupivacaine induced cell 
death.
In summary, our findings suggest that bupivacaine has direct ‘anti-cancer’ properties in vitro. However, our 
work is not without limitations. Firstly, these in vitro experiments do not fully replicate an in vivo or clinical 
environment and thus warrant further study. Secondly, the concentrations of bupivacaine (up to 1 mM) tested in 
this study may not be applicable in particular clinical contexts. LA concentrations vary according to their mode 
of delivery. The concentration of LA on direct infiltration has been reported to reach 500 μ M. It can be even 
higher when administered topically38. An extension of this even though this is beyond the scope of this study is 
to acknowledge that the cancer microenvironment is complex and this in itself is an important determinant in 
tumor growth and metastasis. It has been shown that in the presence of TNF-alpha, a low dose of LA suppressed 
TNF-alpha induced ICAM-1 phosphorylation which is associated with LA anti-migration properties14. Finally, 
regional anesthesia combined general anesthesia with inhalational agents are often used in cancer patients39,40. 
The potential interaction between local anesthetics and inhalational anesthetics on cancer cell biology has not 
been investigated in this study. Interestingly, the survival rate from cancer recurrence is much higher with 
regional anesthesia combined with general anesthesia than with general anesthesia alone9,41. These observations 
are discussed in recently published literature42,43. They indicate that inhalational anesthetics (e.g. isoflurane) may 
promote cancer cell malignancy in vitro. This would require further investigation to establish if they hold true 
in vivo and ultimately in clinical practice. Nevertheless, the data reported here clearly demonstrates that the local 
anesthetic bupivacaine can directly “kill” cancer cells through mechanisms not explored before in this context, 
which is likely to stimulate further research and increase the call for more clinical trials to be conducted.
Materials and Methods
Cell Culture. Human ovarian carcinoma (SKOV-3), prostate carcinoma (PC-3) and human proximal tubular 
cell (HK-2) lines (all purchased from European cell culture collection, Salisbury, UK) were used for this study. 
SKOV-3 were cultured in McCoy’s 5A medium (Sigma Aldrich, St. Louis, USA) and PC-3 and HK-2 were cul-
tured in RPMI-1640 medium (Sigma Aldrich, St. Louis, USA). Culture mediums were supplemented with 10% 
newborn calf serum (HyClone, Auckland, New Zealand) with 1% L-glutamine and 1% penicillin-streptomycin 
(Sigma Aldrich, St. Louis, USA). Cells were maintained at 37 °C under a humidified atmosphere of 5% CO2 and 
95% air in an air jacket incubator (Triple Red, Buckinghamshire, UK). All cells were cultured in 24 wells plate and 
used for experiment when reach 70–80% confluence.
Cells were cultured with bupivacaine at concentrations ranging from 1 μ M to 1 mM for 24 or 72 hours. Other 
cohort cultures were treated with 100 μ M/1 mM bupivacaine or together with 100 nM chemotherapy drug taxol 
Figure 6. Bupivacaine increased GSK-3β, pGSK-3βtyr216 and pGSK-3βser9 activation in ovarian cancer 
(SKOV-3) but not prostate cancer (PC-3) cells. Cells were treated with 1 mM bupivacaine for 24 h followed by 
immunostaining. (A) Total GSK-3β , (B) pGSK-3β tyr216, and (C) pGSK-3β ser9 expression in SKOV-3 cells. (D) Total 
GSK-3β , (E) pGSK-3β tyr216 and (F) pGSK-3β ser9 expression in PC-3 cells. Data are presented by mean ± SD (n = 4). 
***P < 0.001. Scale bar = 50 μ m.
www.nature.com/scientificreports/
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(Sigma Aldrich, St. Louis, USA) or other inhibitors for certain period of time for further experiments described 
below. All treated cultures and the appropriate controls were analyzed for various end-points with the methods 
described below.
FAS, Caspase-8, caspase-9 inhibition. Cells were pre-treated for 30 minutes with FAS neutralizing 
antibody ZB4 (Millipore, Billerica, MA, USA) at a final concentration of 500 ng/ml as previously reported44. 
Other cohort cells were pre-treated with either 20 μ M caspase 8 inhibitor Z-IETD-FMK or caspase 9 inhibitor 
Z-LEHD-FMK (both purchased from R&D Systems Minneapolis, USA) 4 hours followed with 1 mM bupivacaine 
for 24 hours.
Figure 7. GSK-3 inhibitor (SB216763) or GSK-3β siRNA alleviated bupivacaine induced cell death in 
ovarian cancer (SKOV-3) but not prostate cancer (PC-3) cells. Cells were treated with 1 mM bupivacaine and 
20 μ M GSK-3 inhibitor for 24 h. The gene knockdown cells were treated with 1 mM bupivacaine for 24 h. Cell 
survival of GSK-3 inhibition in (A) SKOV-3 and (B) PC-3 cells. (C) Total GSK-3β expression by western blot. 
Cell survival of GSK-3β siRNA treatment in (D) SKOV-3 and (E) PC-3 cells. Data are presented as mean ± SD 
(n = 5). *P < 0.05; **P < 0.01; ***P < 0.001.
www.nature.com/scientificreports/
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GSK-3β inhibition by inhibitor or siRNA. GSK-3 inhibitor (20 μ M) (SB-216763, EMD Millipore Corp, 
Billerica, USA) superposed with 1 mM bupivacaine were given to cultures for 24 hours. Other cells were cultured 
with siRNA (sc-35527, Santa Cruz Biotechnology, CA, USA) targeting GSK-3β or unspecific scramble siRNA 
Figure 8. GSK-3β siRNA decreased the expression of caspase 3, 8, 9 and pGSK-3βtyr216. SKOV-3 cells 
transfected with siRNA were treated with 1 mM bupivacaine for 24 h. (A) pGSK-3β tyr216 (red) and caspase 8, 9 
(green) expression in SKOV-3. (B) pGSK-3β tyr216 (red) and caspase 3 (green) co-expression. (C) The fluorescent 
intensity analysis of pGSK-3β tyr216 and cleaved caspase 3, 8 and 9. Data are presented as mean ± SD (n = 5). 
*P < 0.01; **P < 0.001. Scale bar = 50 μ m.
Figure 9. The proposed molecular mechanisms for bupivacaine induced cancer cell death. Bupivacaine 
induced ovarian cancer (SKOV3) cell death was associated with the activation of caspase 8 and 9, while only 
cleaved caspase 8 involved in prostate cancer cell death. The death pathway induced by bupivacaine is not linked 
to FAS receptor. The phosphorylation of GSK-3β on tyr 216 residue promote the sensitivity of ovarian cancer 
cells to bupivacaine induced cytotoxicity. Dashed line: death pathway for prostate cancer, solid line: death 
pathway for ovarain cancer. FAS-L = FAS ligand; GSK-3β = Glycogen synthase kinase-3β .
www.nature.com/scientificreports/
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dissolved in siRNA suspension buffer supplemented with lipofectamine (Invitrogen, Paisley, UK) to a final con-
centration of 20 nM for 6 h. Afterwards, cells were superposed with 1 mM bupivacaine for 24 hours.
Cell viability and death measurement. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (EMD Chemicals, San Diego, CA) assay reported elsewhere45. MTT was 
dissolved in Opti-MEM (Gibco, Paisley, UK) to form 0.5 mg/ml working solution. Culture medium was removed 
after the incubation with or without indicated concentrations of LA and taxol, then 500 μ L MTT working solu-
tion was added into each well and incubated for 4 hours. Following this, supernatants were aspirated and 500 μL 
DMSO (Fisher Scientific, Leicestershire, UK) was added to dissolve the formazan crystals. In 96 well plates, 
absorbance was measured at 595 nm using micro plate reader analysis (Dynex technologies, Chantilly, VA, USA). 
Cell viability relative to the control was calculated and expressed as relative to control.
For further clarification, Propidium iodide (PI) (Sigma Aldrich, St. Louis, USA) staining was used to examine 
cell death as described previously46. Cells were harvested in a FACS tube and washed twice before re-suspension 
in FACS buffer. PI was added to make the final concentration to 1 μ g/ml and incubated in dark for 5 min. Cells 
were not washed then PI fluorescence was detected using flow cytometry (FL-2 channel). Single color positive 
cells were defined as dead cells.
Immunofluorescence. After treatments, SKOV-3 or PC-3 cells were fixed in 4% paraformaldehyde, then 
blocked with donkey serum in PBST (Sigma Aldrich, St. Louis, USA) for 1 hour followed by the primary antibody: 
rabbit anti-cleaved caspase 3, 8 or 9 (Abcam, Cambridge, UK), mouse anti-caspase 3 (Abcam, Cambridge, UK), 
mouse anti-Ki-67 (Dako, Cambridge, UK), rabbit anti-GSK3β , pGSK-3β ser9 or pGSK-3β tyr216 (Abcam, Cambridge, 
UK) (1:200) in PBST overnight at 4 °C followed by FITC or Rhodamine conjugated secondary antibody 
(Millipore, Watford, UK) (1:400). The slides were counterstained with nuclear dye 4′ ,6-diamidino-2-phenylindole 
(DAPI) and mounted with VECTASHIELD Mounting Medium (Vector Laboratories, Burlingame, CA) and 
then examined using an Olympus BX4 microscope (Watford, UK). Immunofluorescence was quantified using 
ImageJ (National Institutes of Health, Bethesda, MD, USA). Ten representative regions per section were randomly 
selected by an assessor blinded to the treatment groups. Values were then calculated and expressed as relative to 
control.
Reactive oxygen species measurement. Intracellular reactive oxygen species (ROS) generation was 
detected by flow cytometry with 5- (and -6)-carboxy-2′ ,7′ -dichlorofluorescein diacetate (DCFH-DA) (Sigma 
Aldrich, St. Louis, USA) probe. Briefly, cells were washed twice with pre-warmed Dulbecco’s phosphate-buffered 
saline (DPBS) (Sigma Aldrich, St. Louis, USA). 10 μ M DCFH-DA was added into FACS tube to stain cells in 
dark for 30 min at 37 °C. Immunofluorescence intensity was acquired and analyzed using flow cytometry 
(FACSCalibur; Becton Dickinson, Sunnyvale, CA). Each trial had at least 10,000 gated events.
Wound healing assay. Capability of migration was evaluated by wound healing assay reported previously47. 
Briefly, cells were cultured in a 60 mm petri dish to form a confluent monolayer. Then, a wound was scratched 
on this monolayer by 1 ml pipet tip and washed twice with culture media. Before taking each image, a mark was 
made at the bottom of the dish to make sure that all the images were taken at the same site. After another 24 hours 
incubation with or without various concentrations of bupivacaine, the second image was taken at the same site. 
The wound healing status was compared by Image-Pro Plus software (Media Cybernetics, USA) based on these 
images. The results were presented as (initial wound area − remaining wound area)/(initial wound area).
Western blot. Cell samples were homogenized in lysis buffer. Cell lysates were centrifuged with the super-
natant being collected. Then protein concentration was quantified in the supernatant by Bradford protein 
assay (Bio-Rad, United Kingdom). Protein extracts (40 μ g per sample) were heated, denatured, and loaded on 
a NuPAGE 4 to 12% Bis-Tris gel (Invitrogen, USA) for electrophoresis and transferred to a polyvinylidene dif-
luoride membrane. The membrane was blocked with 5% non-fat milk for 1 h at room temperature and then 
probed with rabbit anti-cleaved caspase-3 and mouse anti-GSK-3β (1:1000; Santa Cruz, USA) primary antibody 
in tris-buffered saline and Tween-20 overnight at 4 °C, followed by the application of goat anti-rabbit or goat 
anti-mouse horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The loading con-
trol was protein GAPDH (1:10,000; Millipore, USA). The blots were detected with enhanced chemiluminescence 
system (Santa Cruz, USA) and analyzed with GeneSnap (Syngene, United Kingdom). Protein band intensity was 
normalized with GAPDH and expressed as a ratio of control.
Statistical analysis. All data were expressed as Mean ± SD. Data were analyzed by one-way analysis of var-
iance, followed by the post hoc Student–Newman–Keuls test (GraphPad Prism 5.0 software, San Diego, CA) for 
comparison with Bonferroni corrections. A p value < 0.05 was considered to be statistically significant.
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